Close Menu

NEW YORK (GenomeWeb) – SQream Technologies said today that it has raised $7.4 million in private funding , which it will use to grow its business, particularly in North America.

San Francisco-based Blumberg Capital led the funding With the investment, Alon Lifshitz, a partner at Blumberg Capital, will join SQream's board of directors. To date, SQream has raised $11 million from investors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.